About Mitochondrial fission regulator 2
Mitochondrial fission regulator 2 (MTFR2) is a protein
from Homo sapiens identified by UniProt accession
Q6P444, 385 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Mitochondrial fission regulator 2 |
|---|
| UniProt accession | Q6P444 |
|---|
| Gene | MTFR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 385 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- intraocular pressure measurement · score 0.14
- open-angle glaucoma · score 0.13
- glaucoma · score 0.12
- lung adenocarcinoma · score 0.09
- hepatocellular carcinoma · score 0.09
- esophageal squamous cell carcinoma · score 0.08
- breast cancer · score 0.08
- gonorrhea · score 0.08
- oral squamous cell carcinoma · score 0.06
- neoplasm · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6P444-F1 | alphafold | PREDICTED | 61.80 | — |
Amino-acid sequence (385 residues)
MSLILNILRE MLEYFGVPVE QVLLIWENKD YGSTRSIVRI IGKMLPLEPC RRPNFELIPL LNSVDSDNCG SMVPSFADIL YVANDEEASY LRFRNSIWKN EEEKVEIFHP LRLVRDPLSP AVRQKETVKN DLPVNEAAIR KIAALENELT FLRSQIAAIV EMQELKNSTN SSSFGLSDER ISLGQLSSSR AAHLSVDPDQ LPGSVLSPPP PPPLPPQFSS LQPPCFPPVQ PGSNNICDSD NPATEMSKQN PAANKTNYSH HSKSQRNKDI PNMLDVLKDM NKVKLRAIER SPGGRPIHKR KRQNSHWDPV SLISHALKQK FAFQEDDSFE KENRSWESSP FSSPETSRFG HHISQSEGQR TKEEMVNTKA VDQGISNTSL LNSRI
Explore Mitochondrial fission regulator 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets